HK Stock Market Move | ZAI LAB(09688) rises over 3%, will present first clinical data for ZL-1503 at the 2026 ACAAI meeting.

ZAI LAB(09688) rose over 3%, up 3.03% as of press time, at HK$18.01, with a turnover of HK$17.7074 million. On the news front, according to ZAI LAB's official WeChat account, on October 14, ZAI LAB announced that the first clinical study data evaluating ZL-1503 will be presented for the first time at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting. ZL-1503 is an internally developed bispecific antibody targeting interleukin-13 (IL-13) and interleukin-31 (IL-31) receptor alpha. The meeting will be held from November 12 to 16, 2026, in Phoenix, Arizona, USA. The Phase 1/1b first-in-human trial results in healthy volunteers to be presented at the ACAAI 2026 meeting will include pharmacokinetic data after single dosing, as well as pharmacodynamic data on AD-related biomarkers at different ZL-1503 doses. The ACAAI presentation will also include preliminary safety and immunogenicity data.